Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

Y0000439

Didanosine

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

2′,3′-Dideoxyinosine, ddI, ddIno

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C10H12N4O3
Número de CAS:
69655-05-6
Peso molecular:
236.23
Beilstein:
3619529
Número MDL:
MFCD00077728
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329830956
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

didanosine

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

OC[C@@H]1CC[C@@H](O1)n2cnc3C(=O)NC=Nc23

InChI

1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1

Clave InChI

BXZVVICBKDXVGW-NKWVEPMBSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Didanosine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Y0000440

Didanosine for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0000442

Didanosine impurity G, European Pharmacopoeia (EP) Reference Standard

Y0000441

Didanosine impurity A,, European Pharmacopoeia (EP) Reference Standard

1191204

Didanosine, United States Pharmacopeia (USP) Reference Standard

1191237

Didanosine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1191215

Didanosine System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

1191226

Didanosine Related Compound A, United States Pharmacopeia (USP) Reference Standard

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Masahiko Okiyama et al.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 120(2), 115-122 (2002-08-22)
An active metabolite, ddATP, of didanosine that is an analogue of purine-nucleoside (a component of nucleic acid) was known to inhibit the activity of DNA polymerase for E. coli. In 1985, Dr. Michiya et al. of NCI reported that didanosine
C M Perry et al.
Drugs, 52(6), 928-962 (1996-12-01)
Didanosine is a dideoxynucleoside analogue, which is phosphorylated to the active metabolite dideoxyadenosine triphosphate (ddATP) intracellularly. At therapeutic concentrations, ddATP inhibits HIV replication by inhibiting HIV reverse transcriptase. Didanosine is established as a first-line treatment for patients with HIV disease
M Youle
Antiviral therapy, 3 Suppl 4, 35-37 (2000-03-21)
The current focus on simplifying treatment regimens for patients with human immunodeficiency virus (HIV) infection has contributed to the interest in once-daily therapy. The triphosphate of didanosine (2',3'-dideoxyinosine or DDI) has a long intracellular half-life, which supports the use of
Patricia Pecora Fulco et al.
The Annals of pharmacotherapy, 37(9), 1325-1328 (2003-08-19)
To evaluate the pharmacokinetic interaction between tenofovir and didanosine when used in combination as a highly active antiretroviral therapy regimen. Literature retrieval was accessed through MEDLINE (1966-January 2003) using the terms tenofovir and didanosine. Abstracts from recent meetings, including the
M Masiá et al.
International journal of STD & AIDS, 16(9), 646-648 (2005-09-24)
The combination of tenofovir and didanosine results in an increase in the didanosine plasma exposure and might augment the risk for didanosine toxicity. Although pharmacokinetic studies support a didanosine dose reduction to 250 mg when used concurrently with tenofovir in
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico